Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
or

Actinium Pharmaceuticals Inc (ATNM)

Actinium Pharmaceuticals Inc (ATNM)
1.3000 -0.0100 (-0.76%) 04/28/25 [NYSE Arca]
1.3100 x 1,000 1.3500 x 600
Realtime by (Cboe BZX)
1.3100 x 1,000 1.3500 x 600
Realtime 1.3000 unch (unch) 16:02 ET
Cash Flow for Mon, Apr 28th, 2025
Try Excel Barchart for Excel
Watch
    Add or delete the symbol from one or more Watchlists.

Fiscal Year End Date: 12/31

(Values in U.S. thousands)
  12-2024 12-2023 12-2022 12-2021 12-2020
Cash Flows From Operating Activities
Net Income -38,243 -48,818 -33,017 -24,774 -22,215
Depreciation Amortization 811 790 699 524 447
Other Working Capital -932 -3,149 38,167 1,690 -1,103
Other Operating Activity 5,292 3,842 2,795 1,694 1,254
Operating Cash Flow $-33,072 $-47,335 $8,644 $-20,866 $-21,617
Cash Flows From Investing Activities
PPE Investments -11 -153 -366 -133 -253
Investing Cash Flow $-11 $-153 $-366 $-133 $-253
Cash Flows From Financing Activities
Debt Repayment -9 -4 -49 -85 -460
Common Stock Issued 29,330 14,874 23,158 35,306 76,636
Financing Cash Flow $29,321 $14,870 $23,109 $35,221 $76,176
Beginning Cash Position 76,990 109,608 78,221 63,999 9,693
End Cash Position 73,228 76,990 109,608 78,221 63,999
Net Cash Flow $-3,762 $-32,618 $31,387 $14,222 $54,306
Free Cash Flow
Operating Cash Flow -33,072 -47,335 8,644 -20,866 -21,617
Capital Expenditure -11 -153 -366 -133 -253
Free Cash Flow -33,083 -47,488 8,278 -20,999 -21,870
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Value Investing Philosophies: Graham, Buffett, Bogle, and EMH in Perspective